The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Tafasitamab receives a positive opinion from the EMA CHMP for the treatment of R/R DLBCL
Featured:
Gilles SallesOn June 24, 2021, it was announced that tafasitamab received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for use in combination with lenalidomide to treat adult patients with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant.
The positive opinion recommends the conditional marketing authorization of tafasitamab plus lenalidomide followed by tafasitamab monotherapy. The combination has demonstrated encouraging response rates in the open-label, multicenter, single-arm, phase II L-MIND trial (NCT02399085). Results from this study aided the positive opinion, and the combination was previously approved by the U.S. Food and Drug Administration (FDA) as second-line treatment for adult patients with R/R DLBCL.
For more information on the value of the anti-CD19 monoclonal antibody in the treatment of DLBCL, watch the interview with Lymphoma Hub Chair Gilles Salles, below.
Tafasitamab in DLBCL
References